Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Absorbable Hemostatic Fluid Gelatin Trial

NCT: NCT07830797 · NOT_YET_RECRUITING

NCT IDNCT07830797
StatusNOT_YET_RECRUITING
Start Date2026-09-08
Completion2027-08-31
SponsorMedprin Regenerative Medical Technologies Co., Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

This is a multicenter, single-blind, randomized controlled, non-inferiority trial evaluating the safety and efficacy of an absorbable hemostatic fluid gelatin for surgical hemostasis. Subjects are patients undergoing elective/semi-elective surgeries in General Surgery, Orthopedics, and Gynecology. The test group receives the investigational device, while the control group receives a marketed predicate device (SURGIFLO). The primary outcome is the 5-minute hemostasis success rate at the Target Bleeding Site (TBS).

Frequently Asked Questions

What is Absorbable Hemostatic Fluid Gelatin Trial?

Absorbable Hemostatic Fluid Gelatin Trial is a clinical trial registered under NCT07830797. Current status: NOT_YET_RECRUITING.

What is the status of NCT07830797?

The current status of NCT07830797 (Absorbable Hemostatic Fluid Gelatin Trial) is: NOT_YET_RECRUITING.

When did Absorbable Hemostatic Fluid Gelatin Trial start?

Absorbable Hemostatic Fluid Gelatin Trial started on 2026-09-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.